NasdaqGS:ASNDBiotechs
Ascendis Pharma (ASND) Is Up 5.2% After Revenue Jumps And Losses Narrow In 2025 Results
Ascendis Pharma A/S recently reported fourth-quarter 2025 results, with sales rising to €247.5 million from €173.92 million and the quarterly net loss narrowing to €33.56 million, while full-year 2025 sales increased to €720.13 million and the annual net loss narrowed to €228.03 million.
Despite still operating at a loss, Ascendis cut its basic loss per share from €6.53 to €3.76 over 2025, highlighting how rapid revenue growth from its endocrinology portfolio is helping to improve earnings...